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Isolated limb perfusion (ILP) with melphalan and tumor necrosis factor (TNF)-a is used to treat bulky, locally advanced
melanoma and sarcoma. However, TNF toxicity suggests a need for better-tolerated drugs. Cilengitide (EMD 121974), a novel
cyclic inhibitor of alpha-V integrins, has both anti-angiogenic and direct anti-tumor effects and is a possible alternative to TNF
in ILP. In this study, rats bearing a hind limb soft tissue sarcoma underwent ILP using different combinations of melphalan,
TNF and cilengitide in the perfusate. Further groups had intra-peritoneal (i.p.) injections of cilengitide or saline 2 hr before
and 3 hr after ILP. A 77% response rate (RR) was seen in animals treated i.p. with cilengitide and perfused with melphalan
plus cilengitide. The RR was 85% in animals treated i.p. with cilengitide and ILP using melphalan plus both TNF and
cilengitide. Both RRs were significantly greater than those seen with melphalan or cilengitide alone. Histopathology showed
that high RRs were accompanied by disruption of tumor vascular endothelium and tumor necrosis. Compared with ILP using
melphalan alone, the addition of cilengitide resulted in a three to sevenfold increase in melphalan concentration in tumor but
not in muscle in the perfused limb. Supportive in vitro studies indicate that cilengitide both inhibits tumor cell attachment
and increases endothelial permeability. Since cilengitide has low toxicity, these data suggest the agent is a good alternative
to TNF in the ILP setting.
Since the continued growth of solid tumors requires angio-
genesis, an anti-angiogenic approach to cancer therapy is log-
ical. Since angiogenesis is mediated in part by adhesion
receptors of the integrin family, including the alpha-V (aV)
integrins,1,2 there is a strong rationale for assessing the effects
of integrin inhibitors in cancer treatment. Cilengitide (EMD
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121974) is a novel cyclic inhibitor of aVb3 and aVb5 integ-
rins with both anti-angiogenic and direct anti-tumor effects.
We here report a series of experiments investigating its use
in combination with melphalan and tumor necrosis factor-a
(TNF) in a sarcoma isolated limb perfusion (ILP) model.
aVb3 and aVb5 integrins mediate the interaction between
endothelial cells and components of the extracellular matrix
(ECM).3,4 Preventing the binding of endothelial cells to ECM
ligands results in apoptosis.5,6 Direct proof of the importance
of aV integrins in tumor growth and endothelial stability
comes from studies employing speciﬁc antibodies. For exam-
ple, in a chick chorioallantoic membrane (CAM) assay, the
antibody LM609 (which inhibits aVb3) reduces tumor
growth and invasion,7 and integrin antagonists inhibit angio-
genesis.8,9 The anti-aV-integrin antibody17E6 inhibits mela-
noma development in a mouse model10 and inhibits attach-
ment of endothelial cells to vitronectin and, partially, to
ﬁbronectin.
Integrin aVb3 binds to Arg-Gly-Asp (RGD) in vitronec-
tin, ﬁbronectin and ﬁbrinogen, among other substrates.11–16
RGD cyclic peptides can induce apoptosis in endothelial cells,
inhibit angiogenesis and block tumor growth. One such cyclic
RGD peptide is cilengitide (EMD 121974), Cyclo-(Arg-Gly-
Asp-D-Phe-(N-Me) Val).17–19 Cilengitide disrupts VE-cad-
herin localization at cell junctions, and increases endothelial
monolayer permeability20 and disrupts angiogenesis in vitro21
and in vivo.22 In a tumor-induced CAM assay, it inhibits
cell-matrix contact and angiogenesis.23 Co-administration of
this anti-integrin improved the efﬁcacy of radioimmunother-
apy in breast cancer xenograft24 and glioblastoma orthotopic
xenograft model.25 Importantly, apoptosis of both tumor and
endothelial cells was signiﬁcantly increased.24,26 Most
recently, cilengitide has been shown to reduce the size of
breast cancer bone metastases in a nude rat model and
increase blood vessel permeability on dynamic contrast
enhanced magnetic resonance imaging (DCE-MRI).27,28
ILP with melphalan and TNF is used as salvage therapy
in patients with distributed malignant melanoma or soft tis-
sue sarcoma, and a response rate of 76% has been reported
in locally advanced soft tissue sarcoma.29 We have previously
shown in the ILP system that the alkylating agent melphalan
primarily induces tumor cell death while TNF inﬂicts tumor
vascular damage and endothelial cell death.30,31 The response
rate therefore depends on the direct anti-tumor activity of
melphalan combined with the anti-neovascular activity of
TNF. A consequence of the latter is increased inﬂux of cyto-
toxic agents such as melphalan and doxorubicin into the tu-
mor, which (probably because of high intra-tumoral pressure)
is normally resistant to their access.30,32
Based on the capacity of cilengitide to disrupt active
angiogenic endothelium and trigger endothelial-cell apoptosis
in neovasculature, we investigated whether its addition to
melphalan-based loco-regional treatment of established
BN175 soft tissue sarcomas could improve tumor response
rate. Our results showed that cilengitide administered shortly
before, during and after ILP greatly increased the anti-tumor
activity of melphalan. This synergistic effect was not
explained by altered pharmacokinetics but was associated
with increased levels of melphalan in the tumor compart-
ment. Cilengitide is currently under active investigation as a
systemic agent in randomized phase II and phase III clinical
trials in tumors including squamous cell cancer of the head
and neck and glioblastoma,32–35 in which antitumor activity
has been reported.36
To complement our in vivo ILP studies in sarcoma and
explore possible mechanisms of action underlying the phe-
nomena observed, we carried out a series of in vitro experi-
ments investigating the effects of cilengitide on BN175 cell
adhesion and endothelial permeability. Such effects may
account for the increased tumor response rates seen.
Material and Methods
Drugs
Cilengitide (EMD 121974; cyclic(Arg-Gly-Asp-D-Phe-(N-
Methyl)-Valine) in physiological saline; 15 mg/ml; 25.5 mM)
was provided by Merck KGaA, Darmstadt, Germany, and
further diluted in saline. Melphalan (50 mg per vial) was
diluted in phosphate-buffered saline (PBS) to a concentration
of 2 mg/ml. The recombinant human TNF, kindly provided
by Dr. G. Adolf (Boehringer Ingelheim GmbH, Vienna, Aus-
tria), had a speciﬁc activity of 5  107 U/mg by the murine
L-M cell assay.
Animal tumor model
Male inbred Brown Norway rats (Harlan-CPB, Austerlitz,
The Netherlands) were used at a weight of 250 to 300 g and
fed a standard diet (Hope Farms, Woerden, The Netherlands)
ad libitum. Fragments of the syngeneic BN175 soft tissue
sarcoma (1 mm3) were implanted subcutaneously in the
right hind leg just above the ankle.37 Tumor growth was
measured daily by calipers and volume calculated using the
What’s new?
The growth of solid tumors requires angiogenesis, a process that is mediated in part by the integrin adhesion receptors aVb3
and aVb5, which are inhibited by the drug cilengitide. Cilengitide is known to possess anti-tumor and antiangiogenic effects.
In this study, it was discovered further to increase tumor response rate in a rat model of soft tissue sarcoma, when
administered in conjunction with melphalan. The findings suggest that cilengitide may be a viable alternative to tumor
necrosis factor-a in the treatment of locally advanced sarcoma.
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formula 0.4  (A2  B) where B represents the largest
diameter and A the diameter perpendicular to it. Rats were
sacriﬁced when tumor diameter exceeded 25 mm or at the end
of the experiment (4 weeks). Their temperature was monitored
daily using a transponder implanted intraperitoneally (i.p.;
ELAMS, Electronic Laboratory Animal Monitoring System,
BioMedic Data Systems, Inc., Seaford, DE, USA). All studies
were conducted in accordance with protocols approved by the
Committee on Animal Research of the Erasmus Medical Center.
Treatment protocol
Tumors were allowed to grow to a diameter of 12 to 14 mm
before rats were randomly assigned to the treatment groups
listed in Table 1. These groups were designed to investigate
the effects of perfusing various combinations of melphalan,
TNF and cilengitide with or without the additional i.p.
administration of cilengitide before and after the ILP proce-
dure itself. The i.p. administration pre- and post-ILP was
intended to optimally saturate available aVb3 and aVb5
integrins. Saline was used as a control in both the i.p. and
perfusion settings.
Figure 1 shows the drug administration schedules for the
different groups. During ILP, cilengitide (500 mg, 170 mM),
melphalan (40 mg, 8 mg/ml) and/or TNF (50 mg, 10 mg/ml)
were added to the circuit containing a total volume of 5 ml
Haemaccel (Behring Pharma, Amsterdam, The Netherlands).
Rats were injected i.p. with 50 mg/kg cilengitide or saline
2 hr before and 3 hr after ILP. Figure 1 also shows the times
at which perfusate was sampled for determination of melpha-
lan level, the point at which tissues were taken and the times
before and after ILP when serum was sampled.
Isolated limb perfusion
Animals were anesthetized with Hypnorm and ketamine
(Janssen Pharmaceutica, Tilburg, The Netherlands). The fem-
oral vessels were approached through an incision parallel to
the inguinal ligament after systemic heparin administration
of 50 IU (Leo Pharmaceutical Products, Weesp, The Nether-
lands) to prevent coagulation in the collateral circulation and
in the perfusion circuit. The femoral artery and vein were
cannulated with silastic tubing (0.30 mm inner diameter, 0.64
mm outer diameter; 0.64 mm inner diameter, 1.19 mm outer
Table 1. Treatment groups and tumor response of soft tissue sarcoma-bearing rats after ILP with cilengitide, TNF and melphalan
Group
Therapy regimen Tumor response
i.p Injections1 In perfusate2 PD SD PR CR RR n
A Sham Sham 9 1 0 10
B Sham Cilengitide 4 0 4
C Sham TNF 9 1 1 1 17% 12
D Sham Melphalan 9 2 1 8% 12
E Sham Cilengitide þ TNF 6 0 6
F Sham Cilengitide þ melphalan 3 0 3
G Sham TNF þ melphalan 7 2 1 2 25% 12
H Sham Cilengitide þ TNF þ melphalan 2 1 2 1 50% 6
I Cilengitide Sham 7 0 7
J Cilengitide Cilengitide 14 0 14
L Cilengitide TNF 5 0 5
K Cilengitide Melphalan 5 1 17% 6
M Cilengitide Cilengitide þ TNF3 5 0 5
N Cilengitide Cilengitide þ TNF 10 2 16% 12
O Cilengitide Cilengitide þ melphalan 2 1 2 8 77% 13
P Cilengitide TNF þ melphalan 3 3 100% 6
Q Cilengitide Cilengitide þ TNF þ melphalan 2 0 3 8 85% 13
R Cilengitide before ILP Cilengitide þ TNF þ melphalan 34 1 1 20% 5
S Cilengitide after ILP TNF þ melphalan 3 1 1 40% 5
Animals were treated as depicted in Figure 1.
1Rats were injected i.p. 2 hr before and 3 hr after ILP.
2ILP was started with sham or cilengitide and after 10 min melphalan or TNF was added.
3TNF was added with cilengitide at the beginning of the 30-min perfusion, in contrast to other groups, in which TNF and/or melphalan was present
for only 20 min.
4Although an initial response was observed, rapid regrowth occurred showing PD at day 10.
Abbreviations: ILP, isolated limb perfusion; TNF-a, tumor necrosis factor-a; i.p., intraperitoneal; PD, progressive disease; SD, stable disease; PR,
partial response; CR, complete response; RR, response rate (PR plus CR).
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diameter, respectively; Dow Corning, Ann Arbor, MI, USA).
A tourniquet around the groin temporarily occluded collater-
als. An oxygenation reservoir ﬁlled with 5 ml Haemaccel
and a low-ﬂow roller pump (Watson Marlow type 505 U,
Falmouth, UK) were included in the circuit.
Cilengitide, melphalan and TNF were added as a bolus to
the circuit reservoir. Perfusate was circulated at 2.4 ml/min.
Our previous studies involved perfusion with TNF and
melphalan for 30 min. However, in these experiments ILP
with melphalan and/or TNF lasted 20 min since the ﬁrst 10
min were used to administer cilengitide or saline. A washout
with 5 ml oxygenated Haemaccel was performed at the end
of perfusion. During ILP and washout, the hind leg was kept
at a constant 38 to 39C by a warm-water mattress around
the leg. Limb function was subsequently monitored daily to
assess local toxicity.
Tumor response
Response was classiﬁed as progressive disease (PD) if volume
increased by more than 25%; stable disease (SD) if tumor
remained within 625% of the volume during perfusion;
partial response (PR) if volume decreased by 25 to 90%; and
complete response if volume decreased to less than 10% of
the initial value. The tumor response ratio was calculated by
dividing the tumor volume at day 8 by the volume at day 0.
Tumor response after combined therapy that was greater
than the sum of the responses obtained with the individual
component drugs was taken as evidence of synergy.38
Histopathology
Directly after ILP, tumors were excised, stored in formalin,
and embedded in parafﬁn. Four-micrometer sections were
cut and stained with hematoxylin and eosin using standard
procedures. Three or four tumors in each experimental group
were evaluated blind and at least six slides from each tumor
examined (Leica DM-RXA light microscope) and photo-
graphed (Sony 3CCD DXC 950 camera). Tumor tissues
were also stained for the presence of endothelial cells.
Acetone-ﬁxed frozen sections were post-ﬁxed in 4% parafor-
maldehyde for 30 min and incubated for 1 hr with mouse-
anti-rat CD31PE (Becton Dickinson, Breda, The Netherlands)
diluted 1:50 in PBS with 5% rat serum.
Pharmacokinetics
Serum and perfusate samples were taken from at least three
rats per group at the times shown in Figure 1. Directly after
washout, tumor and part of the muscle on the infused and
non-infused hind limbs were excised. Samples were immedi-
ately frozen in liquid nitrogen and stored at 80C. Tissues
were homogenized in 2 ml acetonitrile (Pro 200 homoge-
nizer, Pro Scientiﬁc, Oxford, CT) and centrifuged at 2,500 g.
Melphalan was measured in these supernatants and in serum
and perfusate samples by gas chromatography-mass spec-
trometry (GC-MS). p-(Bis(2-chloroethyl)amino)-phenylacetic
methyl ester was used as internal standard. Samples were
extracted over tri-functional C18 silica columns. After elution
with methanol and evaporation, the compounds were derivat-
ized with triﬂuoroacetic anhydride and diazomethane in
ether. The stable derivatives were separated on a methylphe-
nylsiloxane GC capillary-column and measured selectively by
single-ion monitoring GC-MS in the positive EI mode.39
Cilengitide in serum was measured using liquid chroma-
tography with tandem mass spectrometry (LC-MS/MS) and
the cyclic peptide cyclo(Arg-Gly-Asp-D-Phe-Val) (c(RGDfV))
as an internal standard. Stock solutions of c(RGDfV) were
prepared in acetonitrile/methanol/water (1:1:1, v/v/v) and
further diluted with methanol/water (2:98, v/v). Aliquots
were mixed with internal standard solution (1:80, v/v),
extracted over an Oasis HLB column (50  1 mm; Waters,
Saint-Quentin, France), and resolved on a reversed-phase
column (LiChroCart 30-2 Purospher, RP8e; Merck KGaA,
Darmstadt, Germany) on a gradient from 100% (0.1%) for-
mic acid to 10% (0.1%) formic acid/90% acetonitrile (v/v).
Detection was carried out by multiple reaction monitoring in
the positive ion mode using an API-3000 mass spectrometer
(AB Sciex, Darmstadt, Germany). Mass transitions of MþHþ
Figure 1. Time-line of treatment and sample collection. ILP, isolated limb perfusion; i.p., intraperitoneal; TNF-a, tumor necrosis factor-a.
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m/z 589 to 312 and m/z 575 to 312 (precursor and product
ions) were used for cilengitide and internal standard
c(RGDfV), respectively.
Statistical analysis
Response rates were subjected to analysis-of-variance and
post hoc to the least signiﬁcant difference (LSD) multiple
comparison test. Tumor volume was evaluated by repeated
measures analysis of variance on days 4, 8 and 12. All statis-
tical tests were two-sided; p < 0.05 was considered signiﬁ-
cant. The possible synergy of combined treatment was
assessed as described previously.38 Data were analyzed by the
Mann-Whitney U test (exact signiﬁcance [2  (one-tailed
signiﬁcance)]) using SPSS version10.0 for Windows 2000.
Calculations were performed using GraphPad Prism v3.0 and
SPSS v11.0 for Windows 2000.
Associated in vitro studies
Cell attachment and attachment inhibition assays were con-
ducted to conﬁrm that the target integrins are expressed by
BN175 sarcoma cells and to investigate the inhibition of cell
adhesion by cilengitide. BN175 cells in log-phase growth
were harvested, washed and re-suspended in culture medium
(RPMI-1640 supplemented with 0.5% bovine serum albumin
[BSA]). In culture medium, 2.5  104 cells per well were
allowed to adhere for 1 hr at 37C onto 96-well plates pre-
coated with the ECM molecules human plasma ﬁbronectin,
vitronectin or laminin I (Sigma-Aldrich, Zwijndrecht, The
Netherlands) before washing free of non-attached cells and
quantiﬁcation by assay for lysozomal hexosaminidase against
an external standard curve.40 To assay for adhesion inhibi-
tion, 96-well plates were coated with vitronectin (2 mg/ml)
and 2.5  104 cells per well allowed to adhere for 1 hr in the
presence of serially diluted cilengitide before washing and
quantiﬁcation of attached cells as above.
The in vitro response of endothelial and tumor cells to cil-
engitide was also investigated. BN175 cells were cultured in
RPMI-1640 supplemented with 10% fetal calf serum (Cam-
brex Bio Science, Verviers, Belgium). Human umbilical vein
endothelial cells (HUVEC) were isolated by collagenase diges-
tion.41 Each isolate was derived from an individual umbilical
vein and used for experiments at passage 5 or 6. HUVEC
were cultured in medium containing human endothelial-SFM
(Invitrogen, Breda, The Netherlands), 20% heat-inactivated
newborn calf serum, 10% heat-inactivated human serum
(Cambrex Bio Science, Verviers, Belgium), 20 ng/ml human
recombinant basic ﬁbroblast growth factor (Peprotech EC
Ltd, London, UK), 100 ng/ml human recombinant epidermal
growth factor (Peprotech EC Ltd). HUVEC were cultured on
plates coated with vitronectin (1 mg/ml; Promega, Leiden,
The Netherlands), ﬁbronectin (10 mg/ml; Roche Diagnostics,
Almere, The Netherlands) or gelatin (10 mg/ml; Sigma,
Zwijndrecht, The Netherlands).
BN175 cells and HUVEC were added in 100-ml aliquots
to 96-well plates at 6  103 cells per well and allowed to
grow for 24 hr. Cells were incubated at 37C in 5% CO2 for
72 hr in the continuous presence of various concentrations of
cilengitide and melphalan in a total volume of 100 ml. Cell
growth was measured using the Sulforhodamine-B (SRB).42
The optical density was read at 540 nm. Cell growth was cal-
culated using the formula: cell growth ¼ (OD test well/OD
control)  100 percent. The drug concentration reducing ab-
sorbance to 50% of the control (IC50) was determined from
the growth curves. The experiments were repeated at least
ﬁve times.
To evaluate transendothelial monolayer-permeability,
HUVEC were plated in a transwell (Corning BV, Schiphol,
The Netherlands; 0.4 mm pore size, 6.5 mm diameter, polyes-
ter ﬁlters), coated with vitronectin (1 mg/ml) or ﬁbronectin
(10 mg/ml), at a density of 1.2  104 cells per well. In the
lower compartment, 1 ml of HUVEC medium was added.
Two days after seeding, a conﬂuent monolayer had formed.
Non-adhering cells were removed and the medium replaced
with 250 ml of 50, 5, 0.5 or 0 mg/ml cilengitide together with
50 ml ﬂuorescein (0.5 mg/ml). At 0.25, 0.5, 1, 2, 4, 8 and 24
hr, 50 ml medium of the lower chamber was taken and ﬂuo-
rescence activity was measured at excitation 490 nm and
emission 530 nm, in a Victor2 1410 multilabel counter (Wal-
lac, Turku, Finland). Induction of permeability was indicated
by a higher concentration of ﬂuorescein in the lower cham-
ber of the transwell, relative to untreated controls.
Results
Tumor response and volume
No responses were observed in sham-treated animals or
when cilengitide was administered alone (either in the perfus-
ate, as an i.p. injection or both) (Table 1, groups A, B, I and
J). ILP with melphalan alone had a minor effect (8%
response rate [RR] in 12 animals in group D). The likelihood
of response was modestly improved when i.p. cilengitide was
administered before and after melphalan perfusion (RR 17%,
group L).
In the absence of i.p. injection, the addition of cilengitide
to melphalan ILP did not lead to any responses (group F).
However, when ILP with melphalan plus cilengitide was pre-
ceded and followed by i.p. cilengitide (group O), the combi-
nation produced a RR of 77%. Eight of the 13 animals
treated with this regimen had a complete response (CR). The
RR in this group was highly signiﬁcantly greater than the RR
in animals treated with ILP using melphalan alone (17% RR,
p ¼ 0.002) or cilengitide alone (when the RR was 0). The
fact that this RR so greatly exceeded that seen in groups
treated with cilengitide or melphalan alone provided evidence
of synergy, using the deﬁnition described above.
The effect of administering i.p. cilengitide in conjunction
with ILP using cilengitide and TNF (rather than melphalan)
was considerably less, although two CRs were observed
among 12 animals treated (16% RR in group N). The fact
that this combination was only minimally effective may be
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accounted for by the fact that cilengitide and TNF have the
same target, namely tumor endothelial cells.
The activity of ILP with melphalan plus TNF in the ab-
sence of any cilengitide was evident in a RR of 25% (group
G). Interestingly, a previous study found that perfusion with
melphalan plus TNF for the full 30 min resulted in a RR of
around 75% in this model. The shorter duration of exposure
in the present series of experiments may therefore have sub-
stantially reduced activity. However, giving cilengitide pre-
and post-ILP with melphalan plus TNF resulted in a 100%
RR including three CRs in six animals treated (group P).
Among animals receiving i.p. cilengitide before and after ILP
with cilengitide added to melphalan and TNF, the RR was
85%, again including eight CRs (group Q). The RR was con-
siderably lower (20%) when i.p. cilengitide following the ILP
was omitted (group R). Comparison of the 40% RR in group
S with the 100% RR in group P suggests that omitting the
pre-ILP administration of cilengitide also appreciably reduces
the likelihood of response.
Figure 2 shows change in tumor volume over the 12 days
following treatment with cilengitide in combination with ILP.
Volumes were measured daily. In panel A, all groups received
cilengitide as an i.p. injection before and after ILP and also
had cilengitide added as a bolus to perfusate.
Tumor volumes increased steadily over this period in ani-
mals that were treated with cilengitide but did not receive
melphalan or TNF in their ILP (group J in Table 1). A very
similar rate of increase was seen in animals whose ILP con-
tained both cilengitide and TNF (group N). However, ILP
with cilengitide plus melphalan preceded and followed by i.p.
cilengitide suppressed tumor growth for the period of study
(group O); and median tumor volume showed a small
decrease in animals perfused with cilengitide plus both mel-
phalan and TNF (group Q).
Panel B shows tumor volumes for four groups treated
with various combinations of cilengitide and melphalan.
Treatment with cilengitide i.p. pre- and post-ILP using
melphalan alone did not prevent tumor growth (group L).
An intermediate degree of growth inhibition was achieved in
animals treated with melphalan plus cilengitide ILP even in
the absence of i.p. drug (group F). However, only three
animals (all of whom had PD) were studied. Perhaps surpris-
ingly, group D, which had no i.p. cilengitide and ILP with
melphalan alone, showed some inhibition of tumor growth
despite an RR of only 8%.
Although many animals received high doses of cilengitide
both locally and systemically, no toxicities attributable to the
agent were evident through observation of the animals or
assessment of their weight and limb function (data not
shown). A maximum weight loss of 10% was observed with
no difference between the treated groups, and weight loss
recovered in most animals. In addition, no abnormal behav-
ior (motility, hair, lethargy, feces) was observed when cilengi-
tide was given systemically and/or through ILP. In all rats
treated with cilengitide, alone or in combination with
melphalan, limb function remained normal and no edema
was observed.
Histopathology
Histopathology showed no effect on tumor tissue or vascula-
ture in sham-treated animals and in those administered ILP
containing either melphalan or TNF alone (Fig. 3a, left-hand
column). However, the co-administration of cilengitide and
either melphalan or TNF dramatically affected the endothelial
integrity of tumor blood vessels (Figs. 3a and 3b). Hemor-
rhage was observed in all animals treated with cilengitide
combined with melphalan, TNF or both. Immunohistology
revealed clear disruption of the endothelial layers. Large areas
Figure 2. Tumor volume (mean 6 SEM) with time in rats treated with cilengitide in combination with melphalan-based isolated limb
perfusion. (a) All rats received cilengitide (Cil) as an intraperitoneal (i.p.) injection and as bolus in the perfusate. Figures in brackets refer
to the groups listed in Table 1. (b) Different regimens of cilengitide with melphalan were used. The number of animals per group is shown
in Table 1. ILP, isolated limb perfusion; TNF-a, tumor necrosis factor-a; mel, melphalan; SEM, standard error of the mean.
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of tumor necrosis were observed when cilengitide was
combined with melphalan, TNF and melphalan plus TNF
(Supporting Information Fig. 3). These results were conﬁrmed
by TUNEL staining, showing increased numbers of TUNEL
positive cells both stained for CD31 and tumor cells, when cil-
engitide in combination with melphalan was used (data not
shown). However, although ILP with TNF plus cilengitide
resulted in abundant tumor necrosis, this was not translated
into tumor response (groups E, M and N), suggesting that a
cytotoxic agent is required to achieve tumor regression.
Figure 3. Histopathology of soft tissue sarcomas after cilengitide treatment in combination with a melphalan-based ILP. (a) After treatment,
tumors were excised from two rats per group. Hematoxylin and eosin staining showed no effect on tumor or tumor-related vasculature (left
panel, open arrows) when animals were treated with sham, melphalan or TNF alone. Conﬁrming previous results, ILP with melphalan plus TNF
resulted in marked vascular damage (arrow heads) accompanied by hemorrhage and edema (asterisks). Administration of cilengitide (right
panel) alone had no noticeable effect on tumor histology or associated vasculature (open arrow). However, when cilengitide was combined
with melphalan, TNF or melphalan plus TNF massive vascular destruction (open arrows heads) and hemorrhage (asterisks in Supporting
Information Fig. 3) were observed. Original magniﬁcation 40 (bar 50 mm). (b) Damage to tumor-associated vasculature visualized by CD31
staining. Perfusion with cilengitide alone had marginal effect on tumor vessel integrity or diameter (closed arrows), while treatment with a
combination of cilengitide and melphalan, TNF or melphalan plus TNF resulted in profound loss of vascular integrity (open arrows) and
widening of the vascular lumen (arrow head). Original magniﬁcation 16 (bar 100 mm). TNF-a, tumor necrosis factor-a; mel, melphalan.
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The inﬂammatory response in tumor tissue after ILP was
studied by analyzing the accumulation and distribution of
leukocytes. Only the number of granulocytes was signiﬁcantly
affected by the treatment. Only in the cilengitide alone
treated group (group J) granulocytes increased signiﬁcantly at
0 hr and 12 hr after ILP compared with no cilengitide. At 24
hr and 48 hr granulocyte numbers decreased rapidly, which
recovered at 72 hr (data not shown).
Pharmacokinetics
To investigate the mechanisms underlying the improved
response resulting from the addition of cilengitide to melpha-
lan-based ILP, intratumor levels of melphalan were measured.
ILP with melphalan alone resulted in a mean 0.6 mg melpha-
lan per gram tumor tissue (Fig. 4). Depending on the dosing
schedule, this rose to between 1.9 and 4.2 mg/g tumor tissue
with the addition of cilengitide. This represents a three to
sevenfold increase relative to group D animals treated with
melphalan ILP alone (p < 0.05). Melphalan level in tumor
was signiﬁcantly increased both by cilengitide added to the
perfusate and by its administration i.p. The effect of adding a
bolus of cilengitide to the perfusate was comparable to that
of co-perfusing melphalan and TNF.
The addition of cilengitide did not signiﬁcantly increase
the concentration of melphalan in healthy muscle from the
ILP-perfused right hind limb. Drug levels in the non-perfused
left hind limb were minimal.
In the rat model studied, the systemic pharmacokinetics
of i.p. cilengitide were not affected by ILP with cilengitide
alone or ILP with cilengitide plus melphalan, TNF or both
(Fig. 5). Systemic cilengitide levels reached around 20mg/ml
(approximately 35 mM) within 10 min of i.p. administration
and continued to rise to approximately 40 mg/ml (approxi-
mately 70 mM) in the ﬁrst hour. Thereafter cilengitide levels
in serum dropped with an elimination half-life of 2.1 hr. The
administration of cilengitide during ILP did not affect
Figure 3. Continued
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systemic levels due to the relatively low concentration used
and the thorough washout at the end of the perfusion. Data
were ﬁtted with a one-phase exponential decay with a good-
ness of ﬁt (R2) of 0.93.
Supportive in vitro studies
The tumor cells used in the present study were shown to
express the integrins targeted by cilengitide. In vitro studies
demonstrated that BN175 rat sarcoma cells attached to surfa-
ces coated with the ECM molecules vitronectin, ﬁbronectin
and laminin. This attachment to vitronectin was inhibited by
cilengitide in a dose-dependent manner with an IC50 of 4mM
(SLG: unpublished data).
The direct effect of cilengitide on BN175 tumor cells and
HUVECs was also investigated. BN175 cells were exposed to
cilengitide alone or combined with melphalan or TNF for 72
hr. A dose–response effect on tumor cells was observed for
cilengitide. The addition of melphalan to cilengitide increased
cell death of both BN175 cells and HUVECs. However, the
addition of TNF had no effect (data not shown). The dose-
dependent growth inhibition of HUVECs by cilengitide
varied according to the matrix on which cells were cultured,
endothelial cells on vitronectin seeming slightly more
sensitive than cells on ﬁbronectin (Supporting Information
Fig. 2a).
In the sarcoma model used, higher tumor response was
associated with an augmented accumulation of melphalan in
tumor tissue. Disruption of the vascular lining was evident
on histology, suggesting that higher melphalan concentrations
resulted from improved intratumoral drug delivery. When
HUVEC monolayers were exposed to 50 mg/ml cilengitide,
which is below the maximum theoretical level reached during
the ILP (100 mg/ml), endothelial permeability increased 3.5-
fold within 30 min, and continued to increase to a maximum
of ﬁvefold in 1 hr (Supporting Information Fig. 2b). At a
cilengitide concentration of 0.5 mg/ml, endothelial cell
morphology had changed so that they no longer adhered on
vitronectin (data not shown).
Discussion
aV integrins are expressed by the active endothelial cells of
the tumor neovasculature, and expression is comparatively
low on quiescent endothelia.3,7–9,43 Agents directed at these
integrins should therefore have a degree of tumor speciﬁcity
in their effects. Cilengitide inhibits cell-matrix contact and
angiogenesis in a tumor-induced CAM assay23 and increases
apoptosis of activated endothelial cells in tumor neovascula-
ture and of tumor cells themselves in animal models.24,26
Exploratory in vivo studies demonstrated that cilengitide
disrupts cell adhesion mediated by aVb3 and aVb5 integrins.
We investigated whether addition of cilengitide to mel-
phalan-based loco-regional treatment of established soft tissue
sarcomas could improve tumor response. A cilengitide–
melphalan combination resulted in a 77% response rate while
cilengitide or melphalan alone resulted in RRs of 0 and 8%,
respectively. Our results show that it is crucial to pre-load
animals with cilengitide, which we suggest saturates available
integrins and pre-sensitizes target cells to melphalan. Tumor
histology showed that the addition of cilengitide to melpha-
lan resulted in loss of vascular endothelial integrity
while leaving normal vessels intact, leading to massive
Figure 4. Accumulation of melphalan in tissue after treatment with
cilengitide and melphalan-based isolated limb perfusion. Values
are shown for tumor, muscle from the non-perfused (left hind limb)
and perfused (right) limb. Data represent mean 6 SEM of six
independent rats measured in duplicate. Both the addition of
cilengitide to the perfusate and its intraperitoneal (i.p.) injection
increased accumulation of melphalan in the tumor but not in
healthy tissue. Cil, cilengitide; ILP, isolated limb perfusion; mel,
melphalan; TNF-a, tumor necrosis factor-a; SEM, standard error of
the mean.
Figure 5. Pharmacokinetics of cilengitide in serum of rats during
treatment as depicted in Figure 1. Bars show mean 6 SD of three
independent rats. Cilengitide was injected 2 hr before and 3 hr
after the period of isolated limb perfusion (hexed region). Serum
concentrations increased sharply after intraperitoneal (i.p.)
injection followed by a single-phase clearance with a half-life of
2.1 hr. Cil, cilengitide; ILP, isolated limb perfusion; Mel,
melphalan; TNF-a, tumor necrosis factor-a; SD, standard deviation.
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intra-tumoral hemorrhage. Tumor vasculature appeared to
have few endothelial cells, consistent with cilengitide-induced
cell detachment.
As has been seen previously with TNF, the addition of cil-
engitide during ILP augmented the accumulation of melpha-
lan in the tumor.30,32 Our data are consistent with previous
observations suggesting that the effect of adding TNF to mel-
phalan-based ILP is due principally to increased accumula-
tion of melphalan in tumor tissue.22 They further suggest
that the same mechanism underlies the enhanced response
rates achieved by the addition of cilengitide to ILP.
This could result from improved perfusion of the tumor
or from increased leakiness of the tumor vasculature. The lat-
ter explanation is supported by the hemorrhaging we
observed and the reported increased permeability of an endo-
thelial monolayer in vitro.20 Recently, cilengitide has been
reported to increase vessel permeability during metastatic
bone colonization in a rat breast cancer model.27The wider
therapeutic importance of any cilengitide-induced increase in
vascular permeability during ILP has still to be demonstrated,
but it is plausible to suggest our results could have implica-
tions for the treatment of, for example, melanoma.
The exploratory in vitro experiments indicate that a direct
effect of cilengitide on tumor cells may also play a role since
cell kill was observed at a relatively low concentration. aV
integrins are involved in processes including attachment,
migration, regulation of matrix metalloproteinase and trans-
forming growth factor (TGF)-b activation, angiogenesis and
apoptosis.8,9,44–48 It is therefore plausible that inhibiting aV-
integrin-ligand interaction should reduce tumor progression.
As a single agent, cilengitide inhibits growth of brain tumors23
and has modest activity in recurrent clinical glioblastoma,36 an
activity which appears to be ampliﬁed by co-therapy with ion-
izing radiation.25,49 In the present study, as in others such as
that of Mikkelsen et al.,25 cilengitide alone did not reduce tu-
mor growth but it is possible that this was because our model
involved only a single short exposure to the drug.
Our data support the view that cilengitide may approach
or match the biologic activity of TNF in ILP. The advantage
of cilengitide over TNF is its lack of toxicity. In patients, cil-
engitide has been reported to be well tolerated up to a dose
of 2,400 mg/m2/infusion.50 If replicated in other therapeutic
contexts, the strong cytotoxic-sensitizing effect of cilengitide,
combined with its tolerability, suggests a potential not only
in ILP but also in the wider context of systemic combination
chemotherapy.
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